Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.58 |
| ▸ | MMP1 | P03956 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16435173 | 1.00 | EPHX2 (0.58) | EPHX2MMP1MMP2MMP8MEN1 | |
| SCHEMBL16435186 | 1.00 | EPHX2 (0.58) | EPHX2MMP1MMP2MMP8MEN1 | |
| SCHEMBL10017777 | 0.98 | EPHX2 (0.56) | EPHX2MMP1MMP2MMP8L3MBTL1 | |
| SCHEMBL16435184 | 0.98 | EPHX2 (0.56) | EPHX2MMP1MMP2MMP8L3MBTL1 | |
| SCHEMBL18909852 | 0.98 | EPHX2 (0.56) | EPHX2MMP1MMP2MMP8L3MBTL1 | |
| SCHEMBL13257060 | 0.93 | EPHX2 (0.56) | EPHX2CYP3A4CYP2C19GAA | |
| Hydrochloric Acid SCHEMBL5205866 | 0.91 | EPHX2 (0.54) | EPHX2CYP3A4CYP2C19GAA | |
| SCHEMBL23241332 | 0.83 | L3MBTL1 (0.44) | EPHX2MMP1MMP2MMP8MEN1 | |
| SCHEMBL8498746 | 0.83 | L3MBTL1 (0.44) | EPHX2MMP1MMP2MMP8MEN1 | |
| SCHEMBL19565377 | 0.83 | EPHX2 (0.44) | EPHX2MMP1MMP2MMP8MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087386-A1 | ROSIN DIESTER COMPOUNDS AND USES THEREOF | FIRMENICH SA (CH) | 2026-04-30 | — | — | WO | disclosed |
| EP-4661972-A1 | TASTE-MODIFYING COMPOSITIONS AND USES THEREOF | Firmenich SA (CH) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024200399-A1 | TASTE-MODIFYING COMPOSITIONS AND USES THEREOF | FIRMENICH SA (CH) | 2024-10-03 | — | — | WO | disclosed |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | 280 BIO, INC. (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | Infex Therapeutics Limited (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-4112308-A1 | INK COMPOSITION, INK SET, AND IMAGE RECORDING METHOD | FUJIFILM Corporation (JP) | 2023-01-04 | — | — | EP | disclosed |
| WO-2022258043-A1 | GEMCITABINE ANTICANCER DERIVATIVE AND ANTICANCER PHARMACEUTICAL USE | 深圳艾欣达伟医药科技有限公司 | 2022-12-15 | — | — | WO | disclosed |
| EP-2496230-B1 | IRE-1 ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-02-26 | — | — | EP | disclosed |
| WO-2020022787-A1 | NOVEL IMIDAZOLE DERIVATIVE HAVING JNK INHIBITORY ACTIVITY, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 삼진제약주식회사 | 2020-01-30 | — | — | WO | disclosed |
| US-10189986-B2 | Acrylamide-based copolymers, terpolymers, and use as hydrate inhibitors | SAUDI ARABIAN OIL COMPANY (SA) | 2019-01-29 | — | — | US | disclosed |
| US-20170321050-A1 | ACRYLAMIDE-BASED COPOLYMERS, TERPOLYMERS, AND USE AS HYDRATE INHIBITORS | SAUDI ARABIAN OIL COMPANY (SA) | 2017-11-09 | — | — | US | disclosed |
| US-20160291019-A1 | System for Detecting Rare Cells | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2016-10-06 | — | — | US | disclosed |
| WO-2016006593-A1 | NOVEL BENZOXAZINE DERIVATIVE AND MEDICINE COMPRISING SAME | 国立研究開発法人国立長寿医療研究センター | 2016-01-14 | — | — | WO | disclosed |
| US-8580905-B2 | Polymers, compositions and methods of use for foams, laundry detergents, shower rinses and coagulants | RHODIA INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8188204-B2 | Polymers, compositions and methods for use for foams, laundry detergents, shower rinses and coagulants | RHODIA INC. (US) | 2012-05-29 | — | — | US | disclosed |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-12-01 | — | — | US | disclosed |
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | INCYTE CORPORATION | 2011-09-15 | — | — | US | disclosed |
| US-7871982-B2 | Lincomycin derivatives and antimicrobial agents comprising the same as active ingredient | MEIJI SEIKA KAISHA, LTD. (JP) | 2011-01-18 | — | — | US | disclosed |
| US-20090156512-A1 | potent activity against resistant pneumococci | MEIJI SEIKA KAISHA, LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-7435735-B2 | Hydroxy pyridopyrrolopyrazine dione compounds useful as HIV integrase inhibitors | MERCK & CO., INC. (US) | 2008-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224189-A1 | SUBSTITUTED CYCLIC HYDROXAMATES AS INHIBITORS OF MATRIX METALLOPROTEINASES | MMP25, MMP14, MMP9 | EPHX2 334/4885MMP1 8/4885MMP2 4/4885 |
| US-20170321050-A1 | ACRYLAMIDE-BASED COPOLYMERS, TERPOLYMERS, AND USE AS HYDRATE INHIBITORS | F12, MTX1, ZYX | EPHX2 628/4885MMP1 906/4885MMP2 1469/4885 |
| US-10189986-B2 | Acrylamide-based copolymers, terpolymers, and use as hydrate inhibitors | F12, MTX1, ZYX | EPHX2 628/4885MMP1 906/4885MMP2 1469/4885 |
| US-20110294749-A1 | DIAMINOPYRIMIDINECARBOXAMIDE DERIVATIVE | STAT6, STAT4, STAT3 | EPHX2 3868/4885MMP1 2982/4885MMP2 1551/4885 |
| US-20090156512-A1 | potent activity against resistant pneumococci | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NAT1, NPM1 | EPHX2 4761/4885MMP1 1186/4885MMP2 1096/4885 |
| US-20230018460-A1 | 1-AMINOSULFONYL-2-CARBOXYPYRROLE DERIVATIVES AS METALLO-BETA-LACTAMASE INHIBITORS | CPN1, CMBL, ALDH7A1 | EPHX2 1889/4885MMP1 794/4885MMP2 346/4885 |
| US-20230278998-A1 | Compound containing structure of a five-membered heteroaromatic ring, pharmaceutical compositions thereof and applications thereof | PARG, CYP3A5, CYP11B1 | EPHX2 315/4885MMP1 4744/4885MMP2 2866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.